medigraphic.com

2003, Number 1

<< Back Next >>

Arch Cardiol Mex 2003; 73 (1)

Effect of ramipril on the glucose/insulin coefficient and the ventricular mass index in patients with light to moderate arterial hypertension

Cardona-Muñoz EG, Noriega-Arellano J, Hernández-Chávez A, López-Alvarado A, González-Ortiz M, Martínez-Abundis E, Delgado Hurtado JM, Ramos-Remus C, Gamez-Nava I, Ayub-Ayala M

Language: Spanish
References: 27
Page: 24-30
PDF size: 76.13 Kb.


ABSTRACT

This longitudinal prospective study was designed to assess the effects of the angiotensin converting enzyme inhibitor (ACEI) ramipril on ventricular mass, left ventricle (LV) diastolic function and blood pressure in patients with mild to moderate essential hypertension and hyperinsulinemia. LV diastolic dysfunction is the first target organ alteration occurring in hypertensive patients, while ventricular hypertrophy is the most relevant predictive factor for cardiovascular morbility and mortality in systemic hypertension. Because several studies have demonstrated that there is no direct correlation between blood pressure values and the severity of LV hypertrophy or diastolic dysfunction, it is assumed that other factors are involved in the genesis of these functional alterations. Moreover, the hypertensive effect of insulin is caused by sympathetic stimulation, sodium and water renal retention and proto-oncogene stimulation leading to myocardial and vascular fibrosis and hypertrophy. We studied 24 hypertensive patients with hyperinsulinemia. All patients underwent an overall and cardiologic clinical evaluation, and electrocardiographic and ecocardiographic studies were performed at baseline and 6 months after being treated with 2.5 to 5 mg/day ramipril. Ramipril treatment significantly reduced systolic (12 mmHg) and diastolic (12 mmHg) pressure levels, basal insulin serum levels (23.62 pmol/dL vs 10.42 pmol/dL), and left ventricle mass index values (143.8 g/m2 vs 118.2 g/m2). Among the variables assessing LV diastolic function, only the transmitral flow E/A wave ratio showed significant differences in women. Ramipril was well tolerated and no significant adverse events were reported.


REFERENCES

  1. Velásquez Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelín Hernández G, Grupo ENSA2000, Fause Attie, Roberto Tapia Conyer. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Card Méx 2002; 72(1): 71-84.

  2. Gonzalez Villalpando G, Stern MP, Arredondo Perez B, Valdez R, Braxton Mitchell B, Haffner S: Prevalence and Detection of Hypertension in Mexico. Arch Med Res 1994; 25(3): 347-353.

  3. Lind L, Berne C, Lithell H: Prevalence of insulin resistance in essential hypertension. J Hypertens 1995; 13: 1457-1462 .

  4. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.

  5. Savage DD, Garrison RJ, Kannel WB et al: The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation 1987; 75 (Suppl. I): 126-133.

  6. MacMahon S, Collins G, Rautaharju P, Cutler J, Neaton J, Prineas R, Crow R, Stamler J: Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factors Intervention Trial. Am J Cardiol 1989; 63: 202-210.

  7. Multiple Risk Factors Intervention Trial Research Group: Multiple Risk Factors Intervention Trial risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.

  8. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.

  9. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK: The progression from hypertension to congestive heart failure. JAMA 1996; 275: 11557-11562.

  10. Vasan RS, Levy D: The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Arch Intern Med 1996; 156: 1789-1796.

  11. Aurigemma GP, Gaasch WH, McLaughlin M, McGinn R, Sweeney A, Meyer TE: Reduced left ventricular systolic pump performance and depressed myocardial contractile function in patients >65 years of age with normal ejection fraction and high relative wall thickness. Am J Cardiol 1995; 76: 702-705.

  12. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH: Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558.

  13. Palatini P, Julius S: Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertension 1997; 11(Suppl 1): S19-S27.

  14. Scherrer U, Owlya R, Lepori M: Body Fat and Sympathetic Nerve Activity. Card Drug and Ther 1996; 10: 215-222.

  15. Lundgren H, Bjorkman L, Keiding P: Diabetes in patients with hypertension receiving pharmacological treatment. BMJ 1988; 297: 1512-1519.

  16. Mykkanen L, Kuusisto J, Pyorala K, Laakso M, Haffner SM: Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens 1994; 12: 1425-32.

  17. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a doublle-blind cross-over study in hypertensive patients. Blood Pressure 1992: 1:92-101.

  18. Pollare T, Lithell H, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989; 298: 1152-1157.

  19. Haenni A, Lithell H: Treatment with a beta-blocker with beta2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994; 43: 455-461.

  20. Lithell HO: Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991, 14: 203-209.

  21. Lithell H: Metabolic aspects of the treatment of hypertension. J Hypertension (Suppl) 1995; 13(2): S77-S80.

  22. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 17: 1595-1607.

  23. The Heart Outcomes Prevention Evaluation Study Investigators. Effects on Angiotensin –Converting-Enzyme Inhibitor, Ramipril, on Death from Cardiovascular Causes, Myocardial infarction, and Stroke in High-Risk Patients. N Engl J Med 2000; 342: 145-153.

  24. The HOPE randomized trial: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril. Ann Intern Med 2001; 134(8): 629-636.

  25. Yusuf S; Gerstein H, Hoogwerf B, Poge J, Bosch J, Wolffenbuttel BH, Zinman B; HOPE Study Investigators. Ramipril and the development of diabetes JAMA 2001; 286(15):1882-5.

  26. HOPE Investigators: Renal Insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.

  27. Gerstein H, Bosch J, Pogue J, et al: Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study. Diabetes Care 1996; 19: 1225-28.




2020     |     www.medigraphic.com